

PATENT  
Customer No. 22,852  
Attorney Docket No. 02481.1832

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: )  
Heiner GLOMBIK, et al. ) Group Art Unit: Unassigned  
Application No.: 10/616,945 ) Examiner: Unassigned  
Filed: July 11, 2003 )  
For: NOVEL THIOPHENE GLYCOSIDE )  
DERIVATIVES, PROCESSES FOR )  
THE PREPARATION, )  
MEDICAMENTS COMPRISING )  
THESE COMPOUNDS, AND THE )  
USE THEREOF )

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)**

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application.

Copies of the listed documents, including any copending patent applications, are attached.

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
[www.finnegan.com](http://www.finnegan.com)



This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and applicants determine that the cited documents do not constitute "prior art" under United States law, applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.


Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

By:

  
\_\_\_\_\_  
Carlos M. Tellez  
Reg. No. 48,638

Dated: January 6, 2004

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
[www.finnegan.com](http://www.finnegan.com)

## INFORMATION DISCLOSURE CITATION

Atty. Docket No.	02481.1832-00000	Appln. No.	10/616,945
Applicant	Heiner GLOMBIK, et al.		
Filing Date	Herewith	Group:	Unassigned

JAN 06 2004  
U.S. TRADEMARK OFFICE

## U.S. PATENT DOCUMENTS

Examiner Initial*		Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriat

## FOREIGN PATENT DOCUMENTS

		Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
	1	EP 1 213 296 A1	12 JUN 02	European			published in English

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

2	Fouda, Hassan G. et al., "Disposition and Metabolism of Tenidap in the Rat," Drug Metabolism and Disposition, 25(2):140-148 (1997).

Examiner	Date Considered
----------	-----------------

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.